Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours

Drug and Alcohol Review

Volumn 30, Issue 3, 2011, Pages 236-245

  Larance, Briony ^a   Degenhardt, Louisa ^b,c   Lintzeris, Nick ^d,e   Winstock, Adam ^f   Mattick, Richard ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BURNET INSTITUTE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d South Eastern Sydney and Illawarra Area Health Service   (Australia)

^e University of Sydney   (Australia)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adherence; Diversion; Misuse; Prescription opioid; Terminology

Indexed keywords

NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

ARTICLE; HUMAN; OPIATE ADDICTION; PAIN; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT;

ANALGESICS, OPIOID; HUMANS; OPIOID-RELATED DISORDERS; PAIN; PATIENT COMPLIANCE; PRESCRIPTION DRUGS;

EID: 79955641980     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/j.1465-3362.2010.00283.x     Document Type: Article

References (108)

1. [1] Drugs and Crime Prevention Committee. Inquiry into the misuse/abuse of benzodiazepines and other forms of pharmaceutical drugs in Victoria. Interim Report. Melbourne: DCPC, Parliament of Victoria; 2006.
2. [2] World Health Organisation. WHO model list of essential medicines: 15th edition (March 2007). Essential Medicines Library. 2007. Available at: (accessed 9 June 2009).
3. [3] American Academy of Pain Medicine and American Pain Soceity. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. 1997.
4. [4] Beubler E, Jaksch W, Devulder J, etal. The European white paper on the use of opioids in chronic pain management. J Pain Palliat Care Pharmacother 2006;20:79-87.
5. [5] Resnik DB, Rehm M, Minard RB. The undertreatment of pain: scientific, clinical, cultural, and philosophical factors. Med Health Care Philos 2001;4:277-88.
6. [6] World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO Press, 2009.
7. [7] World Health Organization. Achieving balance in national opioid drugs control policy: a guideline for assessment. Geneva: World Health Organization, 2000.
8. [8] Ballantyne JC. Opioids for chronic pain: taking stock. Pain 2006;125:3-4.
9. [9] Ballantyne JC. Regulation of opioid prescribing. Br Med J 2007;334:811-12.
10. [10] Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. [see comment]. Pain 2006;125:172-9.
11. [11] Lipman AG. Treatment options for chronic pain management: opioids revisited. Manag Care 2007;16 (Suppl. 3):5-9.
12. [12] The Royal Australasian College of Physicians. Prescription opioid policy: improving management of chronic non-malignant pain and prevention of problems associated with prescription opioids. Sydney: Policy and Advocacy, RACP, 2009.
13. [13] Zador DA, Sunjic SD. Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996. Drug Alcohol Rev 2002;21:131-6.
14. [14] Fugelstad A, Stenbacka M, Leifman A, Nylander M, Thiblin I. Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction 2007;102:406-12.
15. [15] Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20years: risk factors and lives saved. Drug Alcohol Depend 2009;105:9-15.
16. [16] Cone EJ, Fant RV, Rohay JM, etal. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. J Anal Toxicol 2004;28:217-25.
17. [17] Franklin GM, Mai J, Wickizer T, Turner JA, Fulton-Kehoe D, Grant L. Opioid dosing trends and mortality in Washington State Workers' Compensation, 1996-2002. Am J Ind Med 2005;48:91-9.
18. [18] Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006;31:506-11.
19. [19] Lai SH, Teo CES. Buprenorphine-associated deaths in Singapore. Ann Acad Med Singapore 2006;35:508-11.
20. [20] Darke S, Topp L, Ross J. The injection of methadone and benzodiazepines among Sydney injecting drug users 1996-2000: 5-year monitoring of trends from the Illicit Drug Reporting System. Drug Alcohol Rev 2002;21:27-32.
21. [21] Hopwood M, Southgate E, Kippax S, Bammer G, Isaac-Toua G, MacDonald M. The injection of methadone syrup in New South Wales: patterns of use and increased harm after partial banning of injecting equipment. Aust N Z J Public Health 2003;27:551-5.
22. [22] Darke S, Ross J, Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug Alcohol Depend 1996;43:191-8.
23. [23] Humeniuk R, Ali R, McGregor C, Darke S. Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. Addiction 2003;98:413-18.
24. [24] Jenkinson R, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005;100:197-205.
25. [25] Aboltins CA, Daffy JR, Allen P. Fungal endophthalmitis in intravenous drug users injecting buprenorphine contaminated with oral Candida species. Med J Aust 2005;182:427.
26. [26] Feeney GFX, Fairweather P. Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine tablets. Drug Alcohol Rev 2003;22:359-61.
27. [27] International Narcotics Control Board. Narcotic drugs: estimated world requirements 2007. Vienna: United Nations, 2008.
28. [28] Degenhardt L, Larance B, Mathers B, etal. Benefits and risks of pharmaceutical opioids: essential treatment and diverted medication. A global review of availability, extra-medical use, injection and the association with HIV. Thematic paper undertaken on behalf of the Reference Group to the United Nations on HIV and injecting drug use. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2008.
29. [29] World Health Organization. Cancer pain relief. Geneva: World Health Organization, 1986.
30. [30] Selva C. International control of opioids for medical use. Eur J Palliat Care 1997;4:194-8.
31. [31] Mathers B, Degenhardt L, Ali H, etal. HIV prevention, treatment and care services for people who inject drugs: a systematic review of global, regional and national coverage. Lancet 2010;375:1014-28.
32. [32] International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2006. Vienna: United Nations, 2006.
33. [33] Adlaf EM, Hamilton HA, Wu F, Noh S. Adolescent stigma towards drug addiction: effects of age and drug use behaviour. Addict Behav 2009;34:360-4.
34. [34] Corrigan PW, Kuwabara SA, O'Shaughnessy J. The public stigma of mental illness and drug addiction: findings from a stratified random sample. J Soc Work 2009;9:139-47.
35. [35] Dean JC, Rud F. The drug addict and the stigma of addiction. Int J Addict 1984;19:859-69.
36. [36] Room R. Stigma, social inequity and alcohol and drug use. Drug Alcohol Rev 2005;24:143-55.
37. [37] O'Brien CP, Volkow N, Li T-K. What's in a word? Addiction versus dependence in DSM-V. Am J Psychiatry 2006;163:764-5.
38. [38] World Health Organization. Lexicon of alcohol and drug terms. 2009. Available at: (accessed 29 September 2009).
39. [39] American Psychiatric Association. Diagnostic and statistical manual for mental disorders (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
40. [40] World Health Organization. The international classification of diseases, version 10. Geneva: World Health Organization, 1993.
41. [41] American Psychiatric Association. DSM-5 development: proposed draft revisions to DSM disorders and criteria: substance-related disorders. 2010. Available at: (accessed 24 March 2010).
42. [42] Hasin D, Hatzenbuehler ML, Keyes K, Ogburn E. Substance use disorders. In: Saunders J, Schuckit MA, Sirovatka PJ, Regier DA, eds. Diagnostic issues in substance use disorders: refining the research agenda for DSM-V. Arlington, VA: American Psychiatric Association, 2007:93-129.
43. [43] Fainsinger RL, Thai V, Frank G, Fergusson J. What's in a word? Addiction versus dependence in DSM-V. Am J Psychiatry 2006;163:2014-a.
44. [44] Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage 2003;26:655-67.
45. [45] United Nations Office on Drugs and Crime. World drug report 2006. Vienna: United Nations, 2007.
46. [46] Saunders J. Substance dependence and nondependence in DSM and the ICD. In: Saunders J, Schuckit MA, Sirovatka PJ, Regier DA, eds. Diagnostic issues in substance use disorders: refining the research agenda for DSM-V. Arlington, VA: American Psychiatric Association, 2007:75-92.
47. [47] Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth 1998;81:58-68.
48. [48] Savage SR. Opioid therapy of chronic pain: assessment of consequences. Acta Anaesthesiol Scand 1999;43:909-17.
49. [49] Sean Esteban McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health 2006;54:269-78.
50. [50] Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction 2001;96:267-72.
51. [51] McCabe SE, Boyd CJ, Young A. Medical and nonmedical use of prescription drugs among secondary school students. J Adolesc Health 2007;40:76-83.
52. [52] Haydon E, Rehm J, Fischer B, Monga N, Adlaf E. Prescription drug abuse in Canada and the diversion of prescription drugs into the illicit drug market. Can J Public Health 2005;96:459-61.
53. [53] Boyd CJ, Esteban McCabe S, Teter CJ. Medical and nonmedical use of prescription pain medication by youth in a Detroit-area public school district. Drug Alcohol Depend 2006;81:34-45.
54. [54] Sees KL, Di Marino ME, Ruediger NK, Sweeney CT, Shiffman S. Non-medical use of OxyContin tablets in the United States. J Pain Palliat Care Pharmacother 2005;19:13-23.
55. [55] Bruno R. Benzodiazepine and pharmaceutical opioid misuse and their relationship to crime: an examination of illicit prescription drug markets in Tasmania. Tasmania: National Drug Law Enforcement Research Fund, 2004.
56. [56] McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health 2006;54:269-78.
57. [57] The Royal Australasian College of Physicians. Prescription opioid policy: improving the management of chronic non-malignant pain and prevention of problems associated with prescription opioid use. Sydney: The Royal Australasian College of Physicians, 2009.
58. [58] Woolf CJ, Hashmi M. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Investig Drugs 2004;5:61-6.
59. [59] Dasgupta N, Kramer ED, Zalman M-A, etal. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006;82:135-42.
60. [60] Ives TJ, Chelminski PR, Hammett-Stabler CA, etal. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006;6:46.
61. [61] Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College on problems of Drug Dependence Taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003;69:215-32.
62. [62] McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007;32:562-75.
63. [63] Daniulaityte R, Carlson RG, Kenne DR. Initiation to pharmaceutical opioids and patterns of misuse: preliminary qualitative findings obtained by the Ohio Substance Abuse Monitoring Network. J Drug Issues 2006;36:787-808.
64. [64] Degenhardt L, Black E, Breen C, etal. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev 2006;25:403-12.
65. [65] Vlahov D, O'Driscoll P, Mehta SH, etal. Risk factors for methadone outside treatment programs: implications for HIV treatment among injecting drug users. Addiction 2007;102:771-7.
66. [66] Fischer B, Rehm J, Brissette S, etal. Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN Study). J Urban Health 2005;82:250-66.
67. [67] O'Reilly B, Leibrick F, Huxtable D, Chenhall R. Benzodiazepine and pharmaceutical opioid misuse and their relationship to crime: an examination of illicit prescription drug markets in the Northern Territory. NDLERF Monograph No. 20. Tasmania: National Drug Law Enforcement Research Fund, 2004.
68. [68] Moore D, Fraser S. Putting at risk what we know: reflecting on the drug-using subject in harm reduction and its political implications. Soc Sci Med 2006;62:3035-47.
69. [69] Rhodes T. The 'risk environment': a framework for understanding and reducing drug-related harm. Int J Drug Policy 2002;13:85-94.
70. [70] Rhodes T, Singer M, Bougois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med 2005;61:1026-44.
71. [71] Fraser S, Hopwood M, Treloar C, Brener L. Needle fixations: medical constructions of needle fixation and the injecting drug user. Addict Res Theory 2004;12:67-76.
72. [72] McBride AJ, Pates RM, Arnold K, Ball N. Needle fixation, the drug user's perspective: a qualitative study. Addiction 2001;96:1049-58.
73. [73] Topp L. Pharmaceutical diversion: accidental harm reduction? Of Substance 2006;4:6-9.
74. [74] Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp Clin Psychopharmacol 1994;2:244-68.
75. [75] Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC. Epidemiological patterns of extra-medical drug use in the United States: evidence from the National Comorbidity Survey Replication, 2001-2003. Drug Alcohol Depend 2007;90:210-23.
76. [76] Ritter A, Di Natale R. The relationship between take-away methadone policies and methadone diversion. Drug Alcohol Rev 2005;24:347-52.
77. [77] Winstock A. Diversion: what's in a name? Paper presented at APSAD Conference 2006. Cairns, Australia. 2006.
78. [78] Winstock AR, Lea T, Jackson AP. Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics. J Addict Dis 2009;28:57-63.
79. [79] Winstock AR, Lea T, Sheridan J. What is diversion of supervised buprenorphine and how common is it? J Addict Dis 2009;28:269-78.
80. [80] Fraser S. The chronotope of the queue: methadone maintenance treatment and the production of time, space and subjects. Int J Drug Policy 2006;17:192-202.
81. [81] Fraser S, Valentine K, Treloar C, Macmillan K. Methadone maintenance treatment in New South Wales andvictoria: takeaways, diversion and other key issues. Sydney: National Centre for HIV Social Research, University of New South Wales, 2007.
82. [82] Madden A, Lea T, Bath N, Winstock AR. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev 2008;27:671 - 8.
83. [83] Inciardi JA, Surratt H, Kurtz SP, Burke JJ. The diversion of prescription drugs by health care workers in Cinncinati, Ohio. Subst Use Misuse 2006;41:255-64.
84. [84] Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 2007;8:171-83.
85. [85] Lahdenpera TS, Kyngas HA. Compliance and its evaluation in patients with hypertension. J Clin Nurs 2000;9:826-33.
86. [86] Fishman SM, Wilsey B, Yang J, Reisfield GM, Bandman TB, Borsook D. Adherence monitoring and drug surveillance in chronic opioid therapy. J Pain Symptom Manage 2000;20:293-307.
87. [87] Gagne C, Godin G. Improving self-report measures of non-adherence to HIV medications. Psychol Health 2005;20:803-16.
88. [88] Herrmann S, McKinnon E, John M, etal. Evidence-based, multifactorial approach to addressing non-adherence to antiretroviral therapy and improving standards of care. Intern Med J 2008;38:8-15.
89. [89] Duong M, Piroth L, Grappin M, etal. Evaluation of the Patient medication adherence questionnaire as a tool for self-reported adherence assessment in HIV-injfected patients on antiretroviral regimens. HIV Clin Trials 2001;2:128-35.
90. [90] Godin G, Gagne C, Naccache H. Validation of a self-reported questionnaire assessing adherence to antiretroviral medication. AIDS Patient Care STDS 2003;17:325-32.
91. [91] Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 2006;6:48.
92. [92] Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 2006;67:1114-23.
93. [93] Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy R. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviours: a review of the evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guidelines. J Pain 2009;10:131-46.
94. [94] Webster LR, Webster RM. Predicting aberrant behaviours in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6:432-42.
95. [95] Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviours are predictive of current substance use and mental health problems in primary care patients. Pain Med 2008;9:1098-106.
96. [96] Passik SD, Kirsh KL, McDonald MV, etal. A pilot study of aberrant drug-taking attitudes and behaviours in samples of cancer and AIDS patients. J Pain Symptom Manage 2000;19:274-86.
97. [97] Passik SD, Kirsh KL. The need to identify predictors of aberrant drug-related behavior and addiction in patients being treated with opioids for pain. Pain Med 2003;4:186-9.
98. [98] Michna E, Roass EL, Hynes WL, etal. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 2004;28:250-8.
99. [99] Wasan AD, Butler SF, Budman SH, etal. Does report of craving opioid medication predict aberrant drug behaviour among chronic pain patients? Clin J Pain 2009;25:193-8.
100. [100] Meghani SH, Wiedemer NL, Becker WC, Gracely EJ, Gallagher RM. Predictors of resolution of aberrant drug behavior in chronic pain patients treated in a structured opioid risk management program. Pain Med 2009;10:858-65.
101. [101] Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and aberrant drug-related behaviours in medically ill patients with and without histories of substance abuse. Clin J Pain 2006;22:173-81.
102. [102] Turk D, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain 2008;24:497-508.
103. [103] Larance B, Degenhardt L, Mattick RP, etal. The diversion and injection of the pharmaceutical opioids used in opioid substitution treatment: findings from the Australian post-marketing surveillance studies of buprenorphine-naloxone. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2009.
104. [104] Fisher FB. Interpretation of 'abberant' drug-related behaviours. J Am Physicians Surg 2004;9:25-8.
105. [105] Passik SD, Kirsh KL. Assessing aberrant drug-taking behaviours in the patient with chronic pain. Cancer Pain 2004;8:289-94.
106. [106] Spooner C, Hetherington K. Social determinants of drug use. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2005.
107. [107] Wartell J, La Vigne NG. Prescription fraud. Problem-Oriented Guides for Police Problem-Specific Guides Series Guide No. 24. U.S. Department of Justice, Office of Community Oriented Policing Services, May 2004. Available at: (accessed January 2011).
108. [108] Brands B, Rehm J. Towards a consensus on terminology for psychoactive pharmaceutical products abuse. The College on Problems of Drug Dependence, 2007 Meeting. Quebec, Canada. 2007.